Background: The COVID-19 infection is a novel virus that mainly targets the respiratory system via specific receptors without any coronavirus-targeted therapies. Many efforts have …
HU Xichun, HU Zhihuang, W Biyun, W Jialei… - China …, 2022 - china-oncology.com
The corona virus disease 2019 (COVID-19) pandemic continues to severely impact healthcare systems around the world, and patients with cancer are even worse affected …
L Garrigos, C Saura, C Martinez-Vila… - Therapeutic …, 2021 - journals.sagepub.com
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when …
Di [(E)‐arylidene]‐1‐[3‐(4‐methylpiperazin‐1‐yl) alkyl] piperidin‐4‐ones 7 a− k were synthesized through dehydrohalogenation of 1‐(2‐chloroacyl) piperidin‐4‐ones 5 a− k with …
Y Wang, W Cai, P He, Q Cai, J Huang… - … Journal of Cancer, 2024 - Wiley Online Library
Recombinant human granulocyte colony‐stimulating factor (G‐CSF) administration in patients with cancer and coronavirus disease (COVID‐19) remains controversial. Concerns …
M Maki, R Takada, A Taniguchi, N Nomura… - … Health Care and …, 2022 - Springer
Background COVID-19 has become a significant health threat and a primary healthcare concern among the most vulnerable patients with cancer. Patients with COVID-19 who have …
V Zangouri, A Ranjbar, F Homapour… - Medical Journal of the …, 2023 - ncbi.nlm.nih.gov
Background Determining the risk of severe course coronavirus disease 2019 (COVID-19) and its related factors in survivors of common cancers such as breast cancer is important …